Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy

Japanese Journal of Cancer Research

Volumn 90, Issue 12, 1999, Pages 1387-1395

  Nihei, Yukio ^a   Suzuki, Manabu ^a   Okano, Akira ^a   Tsuji, Takashi ^a   Akiyama, Yukio ^a   Tsuruo, Takashi ^b   Saito, Sachiko ^c   Hori, Katsuyoshi ^c   Sato, Yasufumi ^c  

^a AJINOMOTO CO INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Antimitotic; Antivascular; Combretastatin; Tubulin binding agent; Tumor vessel

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUBULIN BINDING AGENT; UNCLASSIFIED DRUG; VINBLASTINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GROWTH INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH; TUMOR NECROSIS;

EID: 0033395393     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00724.x     Document Type: Article

References (25)

1. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L. and Zwi, L. J. Inhibition of growth of colon38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer, 27, 482-487 (1991).
2. Hill, S. A., Lonergan, S. J., Denekamp, J. and Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumor. Eur. J. Cancer, 29A, 1320-1324 (1993).
3. Chaplin, D. J., Pettit, G. R., Parkins, C. S. and Hill, S. A. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br. J. Cancer, 74 (Suppl. XXVII), S86-S88 (1996).
4. Hill, S. A., Sampson, L. E. and Chaplin, D. J. Anti-vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer, 63, 119-123 (1995).
5. Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S. and Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 45, 209-211 (1989).
6. Cushman, M., Nagarathnam, D., Gopal, D., He, H.-M., Lin, C. M. and Hamel, E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J. Med. Chem., 35, 2293-2306 (1992).
7. Woods, J. A., Hadfield, J. A., Pettit, G. R., Fox, B. W. and McGown, A. T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer, 71, 705-711 (1995).
8. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R. and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 10, 1829-1834 (1997).
9. Dorr, R. T., Dvorakova, K., Snead, K., Alberts, D. S., Salmon, S. E. and Pettit, G. R. Antitumor activity of combretastalin-A4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs, 14, 131-137 (1996).
10. Ohsumi, K., Nakagawa, R., Fukuda, Y., Hatanaka, T., Morinaga, Y., Nihei, Y., Ohishi, K., Suga, Y., Akiyama, Y. and Tsuji, T. Novel combretastatin analogues effective against murine solid tumors; design and structure-activity relationships. J. Med. Chem., 41, 3022-3032 (1998).
11. Nihei, Y., Suga, Y., Morinaga, Y., Ohishi, K., Okano, A., Ohsumi, K., Hatanaka, T., Nakagawa, R., Tsuji, T., Akiyama, Y., Saito, S., Hori, K., Sato, Y. and Tsuruo, T. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res., 90, 1016-1025 (1999).
12. Koyanagi, N., Nagasu, T., Fujita, F., Watanabe, T., Tsukahara, K., Funahashi, Y., Fujita, M., Taguchi, T., Yoshino, H. and Kitoh, K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res., 54, 1702-1706 (1994).
13. Bibby, M. C., Double, J. A., Loadman, P. M. and Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J. Natl. Cancer Inst., 81, 216-220 (1989).
14. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133, 95-109 (1988).
15. Hori, K., Saito, S., Nihei, Y., Suzuki, M. and Sato, Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combrestatin A-4 derivative, AC7700. Jpn. J. Cancer Res., 90, 1026-1038 (1999).
16. Andrade, S. P., Hart, I. R. and Piper, P. J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol., 107, 1092-1095 (1992).
17. Tozer, G. M., Prise, V. E. and Chaplin, D. J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res., 57, 948-955 (1997).
18. Peters, C. E. and Chaplin, D. J. Blood flow modification in the SCC2 tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol. Int. J. Radiat. Oncol. Biol. Phys., 22, 463-465 (1992).
19. Dewhirst, M. W., Madwed, D., Meyer, R. E., Ong, E. T., Klitzman, B., Rosner, G. L. and Dodge, R. Reduction in tumor blood flow in skin flap tumor after hydralazine is not due to a vascular steal phenomenon. Radiat. Oncol. Invest., 1, 270-278 (1994).
20. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 47, 3039-3051 (1987).
21. Boucher, Y. and Jain, R. K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implication for vascular collapse. Cancer Res., 52, 5110-5114 (1992).
22. Watts, M., Woodcock, M., Arnold, S. and Chaplin, D. J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumor secreted factors. Anticancer Res., 17, 71-76 (1997).
23. McGown, A. T. and Fox, B. W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4, and amphethinile. Anticancer Drug Des., 3, 249-254 (1989).
24. Yoshino, H., Ueda, N., Niijima, J., Sugumi, H., Kotake, Y., Koyanagi, N., Yoshimatsu, K., Asada, M., Watanabe, T., Nagasu, T., Tsukahara, K., Iijima, A. and Kitoh, K. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem., 35, 2496-2497 (1992).
25. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N. and Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res., 57, 3208-3213 (1997).